DongKook Pharmaceutical Financials
| 086450 Stock | KRW 16,590 240.00 1.47% |
DongKook |
Understanding current and past DongKook Pharmaceutical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DongKook Pharmaceutical's financial statements are interrelated, with each one affecting the others. For example, an increase in DongKook Pharmaceutical's assets may result in an increase in income on the income statement.
Please note, the presentation of DongKook Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DongKook Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of DongKook Pharmaceutical's management manipulating its earnings.
DongKook Pharmaceutical Stock Summary
DongKook Pharmaceutical competes with Samsung Electronics, Samsung Electronics, SK Hynix, SK Holdings, and POSCO Holdings. DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea. DongKook Pharm is traded on Korean Securities Dealers Automated Quotations in South Korea.| Instrument | Korea Stock View All |
| Exchange | KOSDAQ |
| ISIN | KR7086450004 |
| Business Address | 7 Teheran ro |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.dkpharm.co.kr |
| Phone | (82) 2 566 8542 |
| Currency | KRW - South Korean Won |
You should never invest in DongKook Pharmaceutical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of DongKook Stock, because this is throwing your money away. Analyzing the key information contained in DongKook Pharmaceutical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
DongKook Pharmaceutical Key Financial Ratios
DongKook Pharmaceutical's financial ratios allow both analysts and investors to convert raw data from DongKook Pharmaceutical's financial statements into concise, actionable information that can be used to evaluate the performance of DongKook Pharmaceutical over time and compare it to other companies across industries.| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 | |||
| Target Price | 22667.0 | |||
| Beta | 1.09 | |||
| Z Score | 6.0 |
DongKook Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DongKook Pharmaceutical's current stock value. Our valuation model uses many indicators to compare DongKook Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DongKook Pharmaceutical competition to find correlations between indicators driving DongKook Pharmaceutical's intrinsic value. More Info.DongKook Pharmaceutical Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The ratio of Return On Equity to Return On Asset for DongKook Pharmaceutical Co is about 209.16 . Comparative valuation analysis is a catch-all model that can be used if you cannot value DongKook Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DongKook Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.DongKook Pharmaceutical Systematic Risk
DongKook Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DongKook Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on DongKook Pharmaceutical correlated with the market. If Beta is less than 0 DongKook Pharmaceutical generally moves in the opposite direction as compared to the market. If DongKook Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DongKook Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DongKook Pharmaceutical is generally in the same direction as the market. If Beta > 1 DongKook Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
DongKook Pharmaceutical December 15, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of DongKook Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DongKook Pharmaceutical Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of DongKook Pharmaceutical Co based on widely used predictive technical indicators. In general, we focus on analyzing DongKook Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DongKook Pharmaceutical's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 12.55 | |||
| Value At Risk | (3.03) | |||
| Potential Upside | 3.57 |
Complementary Tools for DongKook Stock analysis
When running DongKook Pharmaceutical's price analysis, check to measure DongKook Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DongKook Pharmaceutical is operating at the current time. Most of DongKook Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of DongKook Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DongKook Pharmaceutical's price. Additionally, you may evaluate how the addition of DongKook Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |